Prescribing Information for PAXLOVID (nirmatrelvir / ritonavir) can be found here: Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page. Please note, there are differences between the SmPC for Northern Ireland and the SmPC for Great Britain. Please refer to the appropriate SmPC depending on where you are based.

Paxlovid has a Conditional Marketing Authorisation in Great Britain. A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.

PAXLOVID is taken orally, twice daily for 5 days and can be taken at home1,2Treatment should begin immediately following a positive COVID-19 test and ≤5 days of symptom onset PAXLOVID dosing instructions1,2
  • Paxlovid can be taken with or without food (see section 5.2 of the SmPC (GB or NI))
  • The tablets should be swallowed whole and not chewed, broken, or crushed
  • If a dose is missed and it is within 8 hours of the normal dosing schedule, the patient should take the dose immediately and resume their normal schedule
  • If a dose is missed and it is more than 8 hours after the normal dosing schedule, the patient should not take the missed dose and should instead take their next dose at their regularly scheduled time
  • If a patient requires hospitalization due to severe or critical COVID-19 after starting treatment with Paxlovid, the patient should complete the full 5-day treatment course at the discretion of his/her healthcare provider
  • Nirmatrelvir must be coadministered with ritonavir. Failure to correctly coadminister nirmatrelvir with ritonavir will result in plasma concentrations of nirmatrelvir that will be insufficient to achieve the desired therapeutic effect
The role of ritonavir
  • Ritonavir is administered with nirmatrelvir as a pharmacokinetic enhancer1,2

  • Ritonavir is not active against SARS-CoV-2 3CL protease. It inhibits the CYP3A-mediated metabolism of nirmatrelvir, thereby providing increased plasma concentrations of nirmatrelvir1,2
  • Ritonavir is used in combination with other antivirals to similarly inhibit drug metabolism3
Please consult the relevant SmPC (GB or NI depending on where you are based) for full details before any prescribing decisions are made. 


Find information on dose adjustments here

For Great Britain HCPs only: Search the Interaction Finder to easily search for drug interactions by drug name. 

EXPLORE MORETrial Design & Efficacy

Discover the trial design and efficacy data of EPIC-HR. 

Trial DesignLoadingEfficacyLoading
Dosing Dosing Information Guide

Learn about PAXLOVID dosing, potential drug interactions, and how to prescribe.

Download Loading
GBEducational Resources

Explore downloadable materials to further support both you and your patients. 

Explore more
BadgeSafety Profile & TolerabilityKicker

Learn more about the safety profile and tolerability of PAXLOVID.

Learn more

Drug Interaction Finder

GB HCPs only: Easily search for drug interactions by drug name. 

Search
(GB HCPs Only)
Loading

Example

Footnotes:
COVID-19, coronavirus disease 2019
References:
1.
PAXLOVID GB Summary of Product Characteristics. Pfizer Inc. 
2. PAXLOVID NI Summary of Product Characteristics. Pfizer Inc. 
3. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593.
PP-C1D-GBR-0220. March 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​